The dual PDE3/PDE4 phosphodiesterase inhibitor RPL554 produces more complete bronchodilator responses than the beta2-agonist salbutamol and the anti-muscarinic agent ipratropium bromide, alone and in combination, in guinea-pig isolated trachea Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015
Pharmacological interaction between glycopyrronium bromide and indacaterol fumarate on the human airways tone Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016
Interaction between aclidinium bromide and formoterol fumarate; effects on human bronchial smooth muscle Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014
Budesonide prevents cytokine-induced decrease of the relaxant response to formoterol but not to salmeterol in mouse trachea Source: Annual Congress 2009 - Translational research/biomarkers Year: 2009
Combination study of tiotropium and olodaterol in human precision-cut lung slices Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
A comparison of beta2 -adrenoceptor desensitisation induced by olodaterol and formoterol in human lung mast cells and airway smooth muscle cells Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
The long-acting β2-agonist formoterol re-establishes the anti-proliferative effect of glucocorticoids in asthmatic airway smooth muscle cells (ASMC) Source: Annual Congress 2011 - Understanding disease and drug mechanisms Year: 2011
Beclomethasone, formoterol and glycopyrronium: synergism of triple therapy on human airways Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019
Effects of procaterol or salmeterol added to maintenance tiotropium therapy on small airway functions in COPD patients Source: Annual Congress 2010 - COPD: management Year: 2010
Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline Source: Eur Respir J 2002; 19: 865-871 Year: 2002
Proliferation is not increased in airway myofibroblasts isolated from asthmatics Source: Eur Respir J 2008; 32: 362-371 Year: 2008
Differences in efficacy between formoterol and salmeterol in relaxation of the mouse trachea are accentuated by inflammatory cytokines Source: Eur Respir J 2005; 26: Suppl. 49, 370s Year: 2005
Endothelin-1-mediated contraction of mouse small airways is resistant to salbutamol, but sensitive to rosiglitazone Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013
Indacaterol, a novel inhaled β2-agonist, provides sustained 24-h bronchodilation in asthma Source: Eur Respir J 2007; 29: 871-878 Year: 2007
Impairment of β2 -adrenoceptor agonist relaxation by cytokines is prevented by concomitant glucocorticoid treatment for formoterol but not for salmeterol in mouse trachea Source: Eur Respir J 2007; 30: Suppl. 51, 714s Year: 2007
Interaction between tiotropium bromide and olodaterol in human bronchial smooth muscle Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
Pharmacological characterization of indacaterol, a novel 24-hour β2 -agonist, on isolated human bronchus Source: Eur Respir J 2005; 26: Suppl. 49, 216s Year: 2005
Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014
Anti-inflammatory effect of the combination of a long acting beta2-agonist (salmeterol) and a corticosteroid (fluticasone propionate) on human airway epithelial cells following Staphylococcus aureus infection Source: Eur Respir J 2005; 26: Suppl. 49, 98s Year: 2005
Pharmacological characterization of the mechanism of action leading to synergism between glycopyrronium bromide and indacaterol fumarate Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016